DCK and familial pancreatic carcinoma: Thus, both the simultaneous significant increase in the expression of the activating enzyme (dCK) and the decrease of the deactivating one (5′-NT) suggested a possible role of fluvastatin in the activating metabolism of gemcitabine in pancreatic cancer cells.